Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 16.09 is 39% above its 5-year average of 11.57, near the high end of its 5-year range (7.62–16.09).
46.61% above its 12-month average of 10.97.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 4.40.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-16T00:15:29.924Z. Historical observations retain their original dates. Historical series through 2026-09-11.
EARNINGS PER SHARE (EPS)
16.09
EARNINGS PER SHARE (EPS) AVG TTM
10.97
EARNINGS PER SHARE (EPS) AVG 3Y
11.67
EARNINGS PER SHARE (EPS) AVG 5Y
11.57
EARNINGS PER SHARE (EPS) AVG 10Y
10.66
EARNINGS PER SHARE (EPS) AVG 15Y
9.08
EARNINGS PER SHARE (EPS) AVG 20Y
7.71
CURRENT VS TTM AVG
+46.61%
CURRENT VS 3Y AVG
+37.85%
CURRENT VS 5Y AVG
+39.05%
CURRENT VS 10Y AVG
+50.93%
CURRENT VS 15Y AVG
+77.15%
CURRENT VS 20Y AVG
+108.64%
Amgen Inc.
Market Cap
$202.74B
Earnings Per Share (EPS)
16.09
TTM Avg
10.97
3Y Avg
11.67
5Y Avg
11.57
Market Cap
$188.86B
Earnings Per Share (EPS)
4.06
TTM Avg
3.38
3Y Avg
2.82
5Y Avg
2.39
Market Cap
$181.64B
Earnings Per Share (EPS)
-2.67
TTM Avg
3.61
3Y Avg
3.85
5Y Avg
3.41
Market Cap
$176.59B
Earnings Per Share (EPS)
3.11
TTM Avg
5.71
3Y Avg
4.66
5Y Avg
4.19
Market Cap
$238.35B
Earnings Per Share (EPS)
18.59
TTM Avg
17.17
3Y Avg
16.90
5Y Avg
17.22
Market Cap
$251.01B
Earnings Per Share (EPS)
6.66
TTM Avg
5.57
3Y Avg
4.27
5Y Avg
3.27
Market Cap
$147.13B
Earnings Per Share (EPS)
5.63
TTM Avg
5.20
3Y Avg
6.66
5Y Avg
6.73
Market Cap
$133.24B
Earnings Per Share (EPS)
8.79
TTM Avg
7.27
3Y Avg
5.84
5Y Avg
5.20
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $202.74B | 16.09 | 10.97 | 11.67 | 11.57 |
| Novo Nordisk A/S (NVO)vs › | $188.86B | 4.06 | 3.38 | 2.82 | 2.39 |
| Gilead Sciences, Inc. (GILD)vs › | $181.64B | -2.67 | 3.61 | 3.85 | 3.41 |
| Abbott Laboratories (ABT)vs › | $176.59B | 3.11 | 5.71 | 4.66 | 4.19 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $238.35B | 18.59 | 17.17 | 16.90 | 17.22 |
| Pfizer Inc. (PFE)vs › | $157.02B | 0.76 | 1.39 | 2.19 | 2.39 |
| AstraZeneca PLC (AZN)vs › | $251.01B | 6.66 | 5.57 | 4.27 | 3.27 |
| Danaher Corporation (DHR)vs › | $147.13B | 5.63 | 5.20 | 6.66 | 6.73 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.24B | 8.79 | 7.27 | 5.84 | 5.20 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.62B | 17.18 | 6.69 | 10.10 | 9.99 |
Trailing EPS (TTM)
$16.09
Forward EPS (Est.)
$23.08
P/E Ratio
23.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 14.33 |
| 2024-12-31 | 7.62 |
| 2023-12-31 | 12.56 |
| 2022-12-31 | 12.18 |
| 2021-12-31 | 10.34 |
| 2020-12-31 | 12.40 |
| 2019-12-31 | 12.96 |
| 2018-12-31 | 12.70 |
| 2017-12-31 | 2.71 |
| 2016-12-31 | 10.32 |
| 2015-12-31 | 9.15 |
| 2014-12-31 | 6.80 |
| 2013-12-31 | 6.75 |
| 2012-12-31 | 5.61 |
| 2011-12-31 | 4.07 |
| 2010-12-31 | 4.82 |
| 2009-12-31 | 4.53 |
| 2008-12-31 | 3.79 |
| 2007-12-31 | 2.83 |
| 2006-12-31 | 2.51 |
| 2005-12-31 | 2.97 |
| 2004-12-31 | 1.86 |
| 2003-12-31 | 1.75 |
| 2002-12-31 | -1.21 |
| 2001-12-31 | 1.07 |
| 2000-12-31 | 1.11 |
| 1999-12-31 | 1.07 |
| 1998-12-31 | 0.85 |
| 1997-12-31 | 0.61 |
| 1996-12-31 | 0.61 |
